Find and reach Cumulus Neuroscience's employees by department, seniority, title, and much more. Inexia aims to develop intranasally administered orexin positive modulators for the treatment of neurological diseases.The orexin system is a key regulator of behavioural arousal, wakefulness and sleep. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. Notably, Dementia Discovery Fund is a 250 million venture capital fund that invests in startups building technologies to treat dementia. Cumulus Neuroscience will use the funds to advance its next-generation integrated physiological and digital biomarker platform. Cumulus Neuroscience is a medical research technology company based in Belfast, United Kingdom. Read More. Operating Status Active. Cumulus Neuroscience notes funding to used to advance next-generation integrated physiological and digital biomarker platform. Phone: +44 28 9264 6600. Biotechnology News Magazine reports the latest biotech, diagnostic news Biotechnology News Magazine Fast 1, 2, 3 Easy Read! CONNECT WITH US. View Cumulus Neuroscience location in Northern Ireland, United Kingdom, revenue, competitors and contact information. Industries. Show more The Companys CSO, Dr Brian Murphy, joined other dementia and digital health experts for the panel Pioneering disease-modifying treatments and digital solutions for dementia. Physiotools is an online exercise software for physical therapy, rehabilitation and fitness. Cumulus Neuroscience provides its partners with a uniquely comprehensive and integrated solution, capturing frequent, objective, longitudinal data across a broad spectrum of domains and modalities. Cumulus Neuroscience Company Profile Founded in The United Kingdom around 2015, Cumulus Neuroscience produces noninvasive hardware and end-user software. In clinical trials it provides the critical data Cumulus Neuroscience, a global digital health company, announces the start of two validation trials CNS-101 and CNS-102 supported by a group of leading global pharma companies and Innovate UK. Cumulus Neurosciences integrated solution is a state-of-the-art platform capable of: capturing frequent, longitudinal measurements of brain activity synchronously with a comprehensive range of functional and symptomatic domains outside of the clinic, and. Cumulus innovative platform provides the critical data and insights needed for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience. Cumulus Neuroscience is a company developing physiological and digital biomarker platforms. Start Free Trial . Percentage Acquired 72%. Chrome Extension. Search Crunchbase. Founded Date 2015. He leads Pfizers Advanced Science group, validating technology platforms and qualifying novel digital endpoints. Cumulus Neuroscience is supported by an advisory group of eight of the world's leading Pharma companies. Resources. Resources. Headquarters: Queens Rd, Belfast, Belfast, BT3 9DT, United Kingdom. Start Free Trial . Start Free Trial . Resources. Last Funding Type Venture - Series Unknown. View more. By Cumulus Neuroscience. CB Rank (Hub) 46,290. Build Query: Funding Rounds . May 4, Cumulus Neuroscience Appoints Dr Ruth McKernan CBE as Chair Read more. Cumulus Neurosciences CEO Ronan Cunningham commented: We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients. Media Kit. Products. Physiotools. Number of Founders 101. Solutions. Industries Neuroscience. 17th June 2021. May 5, 2021 by SharpBrains. Alisa Thoren May 5, 2021. Phone Number +44 (0)28 9264 6600. Cumulus Neuroscience . BELFAST, Northern Ireland, Feb. 10, 2022 /PRNewswire/ Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical trial data and AI-powered insights to accelerate the development of life-changing central nervous system (CNS) therapies, announces that Siggi Saevarsson has been appointed as Chief Operating Officer Cumulus Neuroscience is confident that it can play an important role in assisting its pharma and biotech partners to develop transformational Cumulus Neuroscience Announces 6 million Funding Round. Number of Organizations 74. Cumulus Neuroscience Appoints Dr Ian Campbell to Board of Directors Read more. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. Med-Tech Innovation News. Physiotools is an online exercise software for physical therapy, rehabilitation and fitness. SIC Code 73,738. Founders Brian Murphy, Ronan Cunningham, Ruth McKernan. Keelo offers high intensity gym workouts on your phone. Dementia Discovery Fund Dementia Discovery Fund is a specialist venture capital fund that invests in novel science to create meaningful new medicines. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. Developer of a data-centric brain health tracking technology designed to make simple lifestyle changes to encourage healthy aging of the human brain. Cumulus Neuroscience has 1 Funding Round totaling 6M. The company caters to the pharmaceutical industry. Organization Name . Subscribe to the Crunchbase Daily. Cumulus Neuroscience Announces 6 million Funding Round. Ian has over 15 years of executive experience in the Health and Life Sciences sector. Search Crunchbase. Organization. Cumulus Neuroscience raises $8.3M to develop EEG-based wireless Fitbit for the brain. Company Type For Profit. Belfast-based Cumulus raises 6.9m for its Fitbit for the brain (The Irish Times): . In clinical trials it provides the critical The Los Altos, California-based startups Cumulus Neuroscience | 1,488 followers on LinkedIn. Description. View Cumulus Neuroscience location in Northern Ireland, United Kingdom, revenue, competitors and contact information. Contact Email info@cumulusneuro.com. The company current operating status is Active and registered office is at THE INNOVATION CENTRE, UNIT 4, QUEENS ROAD, BELFAST, NORTHERN IRELAND. Keelo. Percentage of Public Organizations 26%. This addresses the significant unmet need to accelerate the delivery of more effective CNS drugs to patients. Log In. Resources. The latest Tweets from Cumulus Neuroscience (@CumulusNeuro). Products. TCT Magazine. Summary Financials People Technology Signals & News. Belfast, Northern Ireland Cumulus Neuroscience CSO Brian Murphy, Ph.D., commented: Cumulus was founded to provide the optimal suite of tools to measure progression of CNS diseases in patients and bringing Winterlights speech analytics on board represents a significant step forward in this work. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. Resources. Contact Us. Alisa Thoren May 5, 2021. Cumulus Neuroscience is a company developing physiological and digital biomarker platforms. RAPID NEWS GROUP PUBLICATIONS. Number of NAICS Code 54199,541. Salaries, reviews, and more - all posted by employees working at Cumulus Neuroscience. Company formerly known as BrainWaveBank secures further funding from backers. Search Crunchbase. Add Funding Rounds filter . Pricing. CUMULUS NEUROSCIENCE LIMITED. Cumulus Neuroscience CEO Ronan Cunningham commented: We are delighted to bring Siggi on board at such an important time for Cumulus. Companies Contacts Investors Funding Rounds Acquisitions People Events Schools Hubs Saved . Company Description: CUMULUS NEUROSCIENCE LIMITED is located in BELFAST, United Kingdom and is part of the Other Ambulatory Health Care Services Industry. Organization Name . Cumulus Neuroscience is the next generation integrated physiological and digital biomarker platform for brain health. It provides critical insights and data to clinical trial, to accelerate the development and delivery of central nervous system (CNS) therapies to patients. (Employees figure is estimated, Sales figure is modelled). Average Founded Date Feb 26, 2005. Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. Save Search . Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. Products. Cumulus Neuroscience is advancing a state-of-the-art platform that can capture physiological and digital biomarkers of disease progression and treatment response in patients, thus providing clinical trial data and AI-powered insights to accelerate the Keelo. Physiotools. It provides novel insights to transform the future of clinical trials in neurodegenerative and neuropsychiatric diseases. Save . Cumulus Neuroscience Ronan Cunningham, CEO & Co-Founder, ronan@cumulusneuro.com Tel: +44 28 9264 6600 Citigate Dewe Rogerson David Dible, Frazer Hall, Nathaniel Dahan Cumulus Neuroscience Announces 6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future. CUMULUS NEUROSCIENCE LIMITED has 21 employees at this location and generates $6.02 million in sales (USD). This is the right choice for small teams and gives access to Pro: the pro Crunchbase package is the most popular and is $29 a month per user. The loss of the orexin neurons has been shown to be strongly linked to multiple neurological conditions including narcolepsy. Log In. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. See what employees say it's like to work at Cumulus Neuroscience. Basic: the basic Crunchbase package is free. FOLLOW US . Cumulus Neuroscience General Information. Cumulus Neuroscience is a company developing physiological and digital biomarker platforms. Utah Insurance Solutions specialize in working with individuals and businesses to help them develop customized insurance plans. Companies Contacts Investors Funding Rounds Acquisitions People Events Schools Hubs Saved . Pricing. Cumulus Neuroscience notes funding to used to advance next-generation integrated physiological and digital biomarker platform. Were developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry. Cumulus Neurosciences CEO Ronan Cunningham commented: We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients. Biotechnology News Magazine reports the latest biotech, diagnostic news Biotechnology News Magazine Fast 1, 2, 3 Easy Read! Solutions. Belfast-based Cumulus raises 6.9m for its Fitbit for the brain. Cumulus Neuroscience Announces 6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund Cumulus Neuroscience receives 1.8m Biomedical Catalyst grant to expand CNS biomarker platform Is this data correct? View more. Pricing. Health Care. Solutions. We have a busy year ahead as we greatly expand the clinical activity for our integrated physiological and digital CNS biomarker platform. Website: www.cumulusneuro.com. Tue May 4 2021 - 12:32. Cumulus Neuroscience Announces 6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund Read more. Cumulus Neurosciences CEO Ronan Cunningham commented: We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients.